Naproxen
Mostrando 25-36 de 76 artigos, teses e dissertações.
-
25. A novel potentiometric naproxenate ion sensor immobilized in a graphite matrix for determination of naproxen in pharmaceuticals
As características, o desempenho e a aplicação de um eletrodo do tipo Pt|Hg|Hg2(NAP)2|Graphite, onde NAP=íon naproxenato, são descritas. O eletrodo responde a NAP com sensibilidade de (58,1± 0,9) mV década-1 no intervalo de 5,0 x 10-5 - 1,0 x 10-2 mol L-1 , a pH 6,0-9,0 e com um limite de detecção de 3,9 x 10-5 mol L-1. O eletrodo é de baixo custo
Journal of the Brazilian Chemical Society. Publicado em: 2006-08
-
26. Effect of therapeutic plasma concentrations of non-steroidal anti-inflammatory drugs on the production of reactive oxygen species by activated rat neutrophils
The release of reactive oxygen specie (ROS) by activated neutrophil is involved in both the antimicrobial and deleterious effects in chronic inflammation. The objective of the present investigation was to determine the effect of therapeutic plasma concentrations of non-steroidal anti-inflammatory drugs (NSAIDs) on the production of ROS by stimulated rat neut
Brazilian Journal of Medical and Biological Research. Publicado em: 2005-04
-
27. Estudo do efeito do naproxeno na regeneração da nadadeira caudal do peixe teleosteo Cyprinus carpio (carpa)
The fins of teleosts show a very fast capacity for regeneration, what make them one important and appropriate biologic model for study of the drugs that can affect their development. The rays of fins are formed, for the most part, of collagen and glycosaminoglycans and, as showed on literature reports, some antiinflammatory drugs, steroidal and nonsteroidal,
Publicado em: 2003
-
28. Naproxeno sódico diminui a recorrência da migrânea quando administrado com o sumatriptan
Quarenta a 78% dos pacientes que utilizam sumatriptan para o tratamento agudo das migrâneas ou enxaquecas apresentam recorrência pelo menos ocasionalmente. O uso concomitante de um anti-inflamatório não esteroidal (AINE) tem sido recomendado para reduzir a frequência da recorrência. Sessenta e sete pacientes que haviam tratado com sucesso pelo menos 8
Arquivos de Neuro-Psiquiatria. Publicado em: 2000-06
-
29. Naproxen in osteoarthrosis. Double-blind crossover trial.
In this double-blind crossover trial, naproxen (750 mg/day) was compared to placebo for the treatment of osteoarthrosis of the hip and knee. Patients were randomly assigned to treatment with either naproxen or placebo for 4 weeks and then to treatment with the alternate agent for a second 4-week period. 8 out of 9 objective and subjective measurements of dru
-
30. Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets
The effect of the concentration of hydrophilic (hydroxypropyl methylcellulose [HPMC]) and hydrophobic (hydrogenated castor oil [HCO]) products, fillers (lactose and dibasic calcium phosphate), and buffers (sodium bicarbonate, calcium carbonate, and sodium citrate) on naproxen release rate was studied. Matrix tablets were prepared by double compression, andIn
Springer-Verlag.
-
31. Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis.
The synthesis of gastric and duodenal mucosal prostaglandin E2, prostaglandin I2, and thromboxane B2 during a 60 minute incubation of biopsy specimens, the degree of endoscopic and histological damage, and the anti-inflammatory response were all studied after a four week, double blind study of therapeutic doses of two non-steroidal anti-inflammatory drugs, n
-
32. Chemical gastritis induced by naproxen in the absence of Helicobacter pylori infection.
AIM--To evaluate the histological changes that occur in the antral mucosa of healthy male subjects before and after one week of naproxen administration, using a chemical gastritis score according to the Helicobacter pylori status. METHODS--Nineteen male subjects (mean age 31 years) underwent two endoscopies: one before and the other after one week of naproxe
-
33. Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis.
In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were observed during the trial period. Gastric complaints occurred
-
34. Multicentre trial of naproxen and phenylbutazone in acute gout.
Naproxen 750 mg as a single dose followed by 250 mg three times daily has been compared with phenylbutazone 200 mg four times daily for 48 hours followed by 200 mg three times daily for treatment of acute gout in an open study on 41 patients. The drugs were equally effective with few and relatively mild side effects. Naproxen is a useful alternative agent fo
-
35. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis.
OBJECTIVES--To compare the efficacy and gastroduodenal safety of a fixed-dose combination of diclofenac sodium 50 mg and misoprostol 200 micrograms twice daily with those of piroxicam 10 mg twice daily and naproxen 375 mg twice daily in patients with osteoarthritis. METHODS--A 4 week, randomised, double-blind, parallel-group, multicentre study was conducted
-
36. Penetration of naproxen and salicylate into inflammatory exudates in the rat.
Acute inflammation was induced in rats by subcutaneous implantation of plastic sponges, and the penetration of salicylate and naproxen into the inflammatory exudate was studied after oral dosing with these compounds. The penetration of intravenously administered 22Na and 125I-albumin was also studied. It was found that salicylate and 22Na penetrated very rap